An Open-Label, Multicenter, Expanded Access Program for Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy.

Trial Profile

An Open-Label, Multicenter, Expanded Access Program for Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Bladder cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 06 Jun 2017 Interim safety results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 11 Aug 2016 Status changed from recruiting to completed.
    • 08 Aug 2016 Status changed from completed to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top